Aurora Cannabis (NASDAQ:ACB – Get Free Report) and Pacira BioSciences (NASDAQ:PCRX – Get Free Report) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Volatility & Risk
Aurora Cannabis has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500.
Institutional and Insider Ownership
47.6% of Aurora Cannabis shares are held by institutional investors. Comparatively, 99.7% of Pacira BioSciences shares are held by institutional investors. 0.0% of Aurora Cannabis shares are held by insiders. Comparatively, 6.4% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
Profitability
This table compares Aurora Cannabis and Pacira BioSciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Aurora Cannabis | -23.70% | 3.72% | 3.03% |
| Pacira BioSciences | 5.08% | 10.82% | 6.01% |
Analyst Recommendations
This is a summary of recent recommendations for Aurora Cannabis and Pacira BioSciences, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Aurora Cannabis | 2 | 2 | 1 | 0 | 1.80 |
| Pacira BioSciences | 0 | 10 | 1 | 0 | 2.09 |
Pacira BioSciences has a consensus target price of $33.33, suggesting a potential downside of 8.58%. Given Pacira BioSciences’ stronger consensus rating and higher probable upside, analysts clearly believe Pacira BioSciences is more favorable than Aurora Cannabis.
Earnings and Valuation
This table compares Aurora Cannabis and Pacira BioSciences”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Aurora Cannabis | $247.82 million | 1.31 | -$88.13 million | ($0.98) | -5.04 |
| Pacira BioSciences | $726.41 million | 2.01 | $7.03 million | $0.35 | 104.17 |
Pacira BioSciences has higher revenue and earnings than Aurora Cannabis. Aurora Cannabis is trading at a lower price-to-earnings ratio than Pacira BioSciences, indicating that it is currently the more affordable of the two stocks.
Summary
Pacira BioSciences beats Aurora Cannabis on 12 of the 13 factors compared between the two stocks.
About Aurora Cannabis
Aurora Cannabis is a Canadian cannabis company headquartered in Edmonton, Alberta. Founded in 2006, it grows, processes and sells cannabis products, with a primary focus on medical cannabis and additional sales in Canada’s adult-use market. The company’s products include dried cannabis flower, oils and other cannabis-based formats. Aurora markets products under brands such as Aurora, MedReleaf and San Rafael ’71, and supplies medical cannabis to patients and customers in Canada and international markets, including parts of Europe and Australia.
About Pacira BioSciences
Pacira BioSciences is a biopharmaceutical company focused on non-opioid approaches to pain management and related health needs. Its portfolio includes medicines and a device intended for use in surgical, musculoskeletal and other care settings. The company’s products include EXPAREL, a long-acting bupivacaine formulation used for postsurgical pain management; ZILRETTA, an extended-release corticosteroid injection for knee osteoarthritis pain; and the iovera system, which uses targeted cold to temporarily block peripheral nerves and relieve pain.
Receive News & Ratings for Aurora Cannabis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurora Cannabis and related companies with MarketBeat.com's FREE daily email newsletter.
